| Product Surveillance Registry | — | Medtronic | <1 mi |
| Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products | — | Medtronic | <1 mi |
| A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists | Phase 3 | Colorado Prevention Center | <1 mi |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) | Phase 2/3 | CSL Behring | <1 mi |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Phase 4 | Duke University | <1 mi |
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity | Phase 3 | Novo Nordisk A/S | <1 mi |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Phase 3 | Amgen | <1 mi |
| A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System | N/A | Biosense Webster, Inc. | <1 mi |
| BoxX-NoAF Clinical Trial | N/A | AtriCure, Inc. | <1 mi |
| Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction | Phase 1/2 | Sardocor Corp. | <1 mi |
| Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II | N/A | Shockwave Medical, Inc. | <1 mi |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Phase 3 | Amgen | <1 mi |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Phase 3 | Cytokinetics | <1 mi |
| Quality of Pediatric Resuscitation in a Multicenter Collaborative | — | Children's Hospital of Philadelphia | <1 mi |
| An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| SuperSaturated Oxygen Comprehensive Observational Registry | — | TherOx | <1 mi |
| Promoting Physical Activity and Fitness Among Underserved Latino Families Living in U.S.-Mexico Border Regions | N/A | San Diego State University | <1 mi |
| Cord Clamping Among Neonates With Congenital Heart Disease | N/A | Carl Backes, MD | <1 mi |
| Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin | Phase 3 | AstraZeneca | <1 mi |
| MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) | Phase 3 | Intellia Therapeutics | <1 mi |
| A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | Phase 3 | Boehringer Ingelheim | <1 mi |
| A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF) | N/A | Biosense Webster, Inc. | <1 mi |
| Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation | N/A | Arga Medtech SA | <1 mi |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Phase 3 | AstraZeneca | <1 mi |
| The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | N/A | Cardiac Dimensions, Inc. | <1 mi |
| Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | — | Children's Oncology Group | <1 mi |
| The Sequencing for Detection in Congenital Heart Disease (SD-CHD) Study | N/A | Scripps Translational Science Institute | <1 mi |
| North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | — | Columbia University | <1 mi |
| A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis | Phase 2 | Novartis Pharmaceuticals | <1 mi |
| The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Phase 3 | Johns Hopkins University | <1 mi |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes | Phase 4 | VA Office of Research and Development | <1 mi |
| MYTHS - MYocarditis THerapy With Steroids | Phase 3 | Niguarda Hospital | <1 mi |
| TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I) | N/A | P+F Products + Features USA Inc. | <1 mi |
| National Collaborative to Improve Care of Children With Complex Congenital Heart Disease | — | Children's Hospital Medical Center, Cincinnati | <1 mi |
| Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy | — | Tenaya Therapeutics | <1 mi |
| A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy | Phase 1 | Rocket Pharmaceuticals Inc. | <1 mi |
| Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure | — | Hari Narayan | <1 mi |
| AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM | — | Cordio Medical | <1 mi |
| Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 | Phase 3 | Mezzion Pharma Co. Ltd | <1 mi |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | 7 mi |
| SELUTION 4 De Novo Small Vessel IDE Trial | N/A | M.A. Med Alliance S.A. | 7 mi |
| NORM-HF Pivotal Study | N/A | Foundry Innovation & Research 1, Limited (FIRE1) | 7 mi |
| A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | Phase 3 | Boehringer Ingelheim | 7 mi |
| A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | Phase 3 | Colorado Prevention Center | 7 mi |
| MyGeneRank: A Digital Platform for Next-Generation Genetic Studies | N/A | Scripps Translational Science Institute | 11 mi |
| Assessment of CCM in HF With Higher Ejection Fraction | N/A | Impulse Dynamics | 11 mi |
| Left vs Left Randomized Clinical Trial | N/A | Baylor College of Medicine | 11 mi |
| ViewFlex X ICE First-in-Human Study | — | Abbott Medical Devices | 11 mi |
| A Post-Market Assessment of the Safety and Performance of the TriClip™ System | — | Abbott Medical Devices | 11 mi |
| Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | Phase 3 | Eidos Therapeutics, a BridgeBio company | 11 mi |
| CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) | Phase 3 | Cardiol Therapeutics Inc. | 11 mi |
| ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™ | N/A | JenaValve Technology, Inc. | 11 mi |
| A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM) | Phase 1 | Rocket Pharmaceuticals Inc. | 11 mi |
| Danon Disease Natural History Study | — | Rocket Pharmaceuticals Inc. | 11 mi |
| Encore PFO Closure Device - The PerFOrm Trial | N/A | Encore Medical Inc. | 11 mi |
| A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy | Phase 2 | Novo Nordisk A/S | 11 mi |
| Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360) | N/A | Medtronic Cardiac Ablation Solutions | 11 mi |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | Phase 3 | DalCor Pharmaceuticals | 11 mi |
| XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP) | N/A | XVIVO Perfusion | 11 mi |
| ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve | N/A | Edwards Lifesciences | 11 mi |
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | Phase 3 | X4 Pharmaceuticals | 11 mi |
| Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial | N/A | Edwards Lifesciences | 11 mi |
| Non-Invasive Detection of Right-to-Left Cardiac Shunts | — | Scripps Health | 11 mi |
| Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM | Phase 1/2 | Tenaya Therapeutics | 11 mi |
| A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy | Phase 2 | Imbria Pharmaceuticals, Inc. | 11 mi |
| FORWARD CAD IDE Study | N/A | Shockwave Medical, Inc. | 11 mi |
| A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) | — | Bristol-Myers Squibb | 11 mi |
| A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease | Phase 2 | Rocket Pharmaceuticals Inc. | 11 mi |
| Incidence of Long-TeRm Atrial Fibrillation After Acute Illness | — | University of California, San Diego | 11 mi |
| J-Valve Transfemoral Pivotal Study | N/A | JC Medical, Inc., an affiliate of Edwards Lifesciences LLC | 11 mi |
| AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions | N/A | Boston Scientific Corporation | 11 mi |
| HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry | — | University of Kansas Medical Center | 11 mi |
| TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Phase 3 | Alnylam Pharmaceuticals | 11 mi |
| The ENCIRCLE Trial | N/A | Edwards Lifesciences | 11 mi |
| A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk | Phase 3 | Eli Lilly and Company | 11 mi |
| Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy | Phase 4 | Dennis M. McNamara, MD, MS | 11 mi |
| AMEND TS Early Feasibility Study | N/A | Valcare Medical Ltd. | 11 mi |
| Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study | N/A | AtaCor Medical, Inc. | 11 mi |
| Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System | N/A | Aria CV, Inc | 11 mi |
| Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF) | N/A | Medtronic Cardiac Ablation Solutions | 11 mi |
| LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF | Phase 3 | Tenax Therapeutics, Inc. | 11 mi |
| Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. | N/A | Medtronic Cardiovascular | 11 mi |
| Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure | N/A | Boston Scientific Corporation | 11 mi |
| GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study | N/A | W.L.Gore & Associates | 11 mi |
| Clinical Course Of Disease In Participants With FA-CM | — | Lexeo Therapeutics | 11 mi |
| A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy | Phase 3 | Pierre Fabre Medicament | 11 mi |
| Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | Phase 2 | Regeneron Pharmaceuticals | 24 mi |
| AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF | Phase 2 | Cytokinetics | 34 mi |
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) | Phase 3 | Anthos Therapeutics, Inc. | 34 mi |